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Abstract (250 words) 
In inflammatory autoimmune diseases, bone loss is frequent. In most cases, secondary osteoporosis 
is caused by treatment with systemic glucocorticoid. However, the pathogenesis behind the bone 
loss is presumed multifactorial.  
We aimed to elucidate the role of the P2X7 receptor on bone mineral density (BMD), 
microarchitecture, and bone strength in a standardized mouse model of Inflammation-Mediated 
Osteoporosis (IMO).  
In total 146 mice completed our protocol, 70 wild type (WT) mice and 76 P2X7-/- (knockout, KO). 
BMD at the femur and spine decreased significantly from baseline to day 20 in the WT IMO mice 
(p<0.01). In the WT vehicle, KO vehicle and KO IMO, no significant BMD changes were found. 
Bone strength showed a lower mid-shaft max strength (p=0.038) and also a non-significant trend 
towards lower strength at the femoral neck of the WT IMO group. Trabecular bone volume fraction 
(BV/TV) and connectivity density (CD) after 20 days were significantly decreased in the WT IMO 
group (p=0.001). In contrast, the WT vehicle and KO vehicle, BV/TV and CD did no change at 20 
days. Cortical bone revealed no significant microarchitectural changes after 20 days in the WT IMO 
group, whereas the total cortical area increased significantly in WT vehicle and KO IMO after 20 
days (5.2% and 8.8%, respectively). 
In conclusion, the P2X7 receptor KO mice did not respond to inflammation with loss of BMD 
whereas the WT mice had a significant loss of BMD, bone strength and trabecular 
microarchitecture, demonstrating a role for the P2X7 receptor in inflammatory bone loss. 
 
Key words: P2X7, BMD, IMO, inflammation, osteoporosis, microarchitecture 
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Introduction 
Autoimmune diseases and other chronic inflammatory diseases are often complicated by 
osteoporosis; 10% of rheumatoid arthritis patients are osteoporotic and 25% are osteopenic [1, 2]. 
Several factors are known to influence the risk of bone loss and several of those are often present in 
patients suffering inflammatory diseases i.e. medications, physical inactivity and endocrine factors. 
Glucocorticoids are widely used in the treatment of inflammatory autoimmune diseases, and it is 
well known that the use of glucocorticoids is associated with osteoporosis [3]. Glucocorticoid-
induced osteoporosis (GIO) is the second most common form of osteoporosis and the most common 
iatrogenic form of the disease [3]. However, a meta-analysis has shown an increased incidence of 
osteoporosis in rheumatoid arthritis patients even after correcting for the use of glucocorticoids [4].   
Patients suffering from active inflammatory diseases may also have chronically impaired physical 
activity This relative immobility can further contribute to the bone loss in patients with 
inflammatory diseases. Also, endocrine factors affecting the calcium and bone homeostasis might 
influence the bone remodelling leading to bone loss i.e. low estrogen level, high plasma PTH and 
low plasma 25-OH-vitamin D. However, the inflammatory process itself may induce changes in the 
regulation of bone turnover that consequently may lead to systemic bone loss.The inflammatory 
autoimmune diseases include a group of disorders that share the presence of inflammatory and 
destructive changes that affect the structure and function of articular and periarticular tissues. 
Several proinflammatory cytokines (such as Tumor Necrosis factor alpha (TNFα), interleukin (IL)-
1 and IL-17) are major triggers for osteoclast activation explaining the enhanced bone loss during 
inflammation. Other, such as IL-12, IL-18, IL-33 and interferon alpha2 (IFN), are strong 
suppressors of osteoclast differentiation and inhibit bone loss. Thus the cytokine composition of an 
inflammatory tissue is decisive whether inflammation triggers bone loss or not [5].  
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In recent years, the role of adenosine triphosphate (ATP) and its cognate receptors in the 
inflammatory process has been recognized. In particular, the P2X7 receptor which is expressed on 
the immune cells and bone cells [6] is thought to play an important role in macrophage/microglial 
and granulocyte function by regulating cytokine production and apoptosis [7, 8]. Moreover, as the 
P2X7 receptor is known to be up-regulated during inflammation, antagonists of this receptor may 
serve as novel anti-inflammatory agents [9, 10]. Lister et al have summarised recent advances in the 
understanding of the role of the  P2X7 receptor in inflammatory processes and highlight the 
potential of  P2X7 receptor ligands for the treatment of chronic inflammatory diseases [10]. In the 
immune system, this receptor has been implicated in the processing and release of cytokines such as 
IL-1β, and in the initiation of cell death via both apoptotic and necrotic pathways [10-13]. As such, 
it has been proposed to function as a major regulator of inflammation. Experiments performed in 
vitro and in vivo in P2X7 receptor null mice demonstrated this receptor to be responsible for ATP-
dependent IL-1β release [5, 14]. Furthermore, the P2X7 receptor seems also implicated in the 
release of many other cytokines [10]. In bone, the P2X7 receptor has multiple actions. It is 
expressed in both osteoblasts [15, 16] and osteoclasts [17, 18]. It is involved in intercellular 
communication among osteoblasts [19, 20]. In mouse osteoblasts, P2X7 receptor activation induces 
blebbing of the plasma membrane [21]. Moreover, P2X7 receptors have been shown to mediate 
extra cellular signal-regulated kinase (ERK) 1/2 activation by fluid shear stress [22]. Thus, P2X7 
receptors in osteoblastic cells couple to multiple signaling pathways, some of which are important 
in skeletal mechanotransduction. 
Osteoclasts seem to consistently express P2X7 receptors. In osteoclasts, the P2X7 receptor has a 
more complex role where it has been implicated in cell fusion [14], apoptosis[23], the translocation 
and activation of NFΚB (nuclear factor kappa-light-chain-enhancer of activated B cells)[24] and 
protein kinase C (PKC) [25] and intercellular communication [26]. 
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Consistent with the above, inactivation of the receptor in mice modulates disease pathogenesis in 
several animal models of inflammatory and autoimmune diseases [11]. The aim of this study was 
therefore to investigate the role of the P2X7 receptor in inflammatory mediated bone loss in a 
mouse model of generalized inflammation. 
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Material and Methods 
Animals: 
The study protocol was in compliance with the bioethical guidelines for animal research and was 
approved by the Danish Animal Experiments Inspectorate (Protocol: 2010/561-1907).  
In total 146 mice finalized the study protocol, 70 WT mice and 76 P2X7-/- (KO). Initially eight 
weeks old mice breeding pairs P2X7-/- on a C57bl/6 background from Jackson Laboratories (Bar 
Harbor, ME) were obtained and the intended breeding goal was 75 male P2X7-/- mice. Seventy 
male C57bl/6fBomTac wild type (WT) mice 14 weeks of age from BOM (Taconic, Lille Skensved, 
Denmark) were included as control animals. The animals were kept in a 12 hour light/dark cycle 
with light on at 8 am. The animals were fed ad libitum with standard diet (1319F Altromin) and had 
free access to drinking water (domestic quality tap water). The flow and study groups are presented 
in figure 1. 
The Inflammation-Mediated Osteoporosis model (IMO).  
We induced chronic inflammation by subcutaneous implantation/of a non-specific irritant, TALC 
(Appendix 1) according to the method first published Minne et al [27] and further standardized by 
Amour and Amour [28]. 
The animals were weighed and anaesthetised using Hypnorm/dormicum doses 3 µl/g. Using a 21  
23 G needle, TALC suspension 800 mg/mL or vehicle was injected subcutaneously (s.c.) to a total 
dose of 16 mg/g body weight. One injection of TALC was injected in each side of the animal lateral 
to the spine spreading out the suspension in the length of the needle. Hereafter Calcein (0.8 mg/ml) 
(Appendix 1) was injected intraperitoneally (20 mg/kg) 10 and 2 days before sacrifice. The mice 
were kept fasting over night before sacrifice. On the day of sacrifice the mice were anaesthetized 
and euthanized by cervical dislocation. Blood was drawn by cardiac puncture before cervical 
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dislocation. The blood samples were coagulated for about 10 min before centrifuged and serum 
stored at -20°C. The body weight was measured, BMD was measured by DXA-scanning on a 
PIXImus DXA apparatus (Lunar Corp., Madison, WI, USA) in duplicate measurements and spleen 
was removed and weighted. The spine and hind legs were isolated and were cleansed of soft tissue. 
Right femur was stored wrapped in saline gaze and frozen to -20°C. The spleen and right tibia 
together with fibula were stored in ethanol. Entire left leg and spine were stored in 10% formalin 
and weight of the spleen was measured. 
Analysis 
Bone mineral density (BMD) by Duel X-ray absorptiometry (DXA) 
BMD, bone mineral content (BMC) and bone area measurements were performed using a Lunar 
Piximus densitometer (Lunar Corp., Madison, WI). The total spine was chosen as Region of Interest 
(ROI) spanning from just above os sacrum. The femur was also chosen as a ROI spanning from 
caput to proximal to the condyles above the knee joint. Left femur was chosen, but if TALC 
interfered with the ROI the right femur was used.  The spine was re-scanned in duplicate (4-5 
lowest vertebral bodies), having been stored in 10% formalin. Data were analysed using the 
manufacturer’s software (version 2.0). 
Biomechanical testing (Bone strength): 
Prior to mechanical testing the bones were thawed and rehydrated to approximately 20 °C in saline 
1 day before testing. Bone strength measurements were made using the Lloyd LR 50k (Lloyd 
Instruments, Fareham, UK). They were performed as a 3-point bending test at the femoral mid-shaft 
and as a vertical compression test on the femoral head [29]. 
Load-deformation curves were generated, and maximal load was recorded at a speed of 2 mm per 
minute with a 100 N load cell. Ultimate load is the maximal load (N) the bone can resist before it 
breaks.  
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Micro CT scanning and Microarchitectural analysis 
The femurs and tibiae of mice were dissected free of soft tissue, and stored in 10 % formalin. The 
mid-shaft and the proximal part of left tibia were scanned using a high-resolution micro computed 
tomography (micro-CT) system (vivaCT 40, Scanco Medical AG, Brüttisellen, Switzerland). The 
baseline and the 20 day groups of WT and KO were scanned. The scan resulted in a 3-dimensional 
(3D) reconstruction of cubic voxel sizes of 10.5 * 10.5 * 10.5 μm3 (2048*2048*2048 pixels) with 
32-bit gray levels. Each 3D image dataset consisted of approximately 210 CT slide images. For 
proximal tibial cancellous bone, 100 slide images (1050 μm) beneath the growth plate were used for 
analysis of cancellous bone microarchitecture. For mid-shaft cortical bone, all 210 slice images 
were used for analysis of cortical microarchitecture [30]. The right distal femur were also scanned 
but not analysed.  
Using direct 3D methods the following measures were performed: Bone volume fraction (BV/TV, 
%), trabecular number (Tb.N, per mm), trabecular thickness (TbTh, mm), trabecular separation 
(Tb.Sp, mm), connectivity density (Conn D, mm
-3
) and structural model index (SMI, -) were 
calculated. From the cortical data bone porosity (%), cortical thickness (mm), BS/TV (mm
-1
),  pore 
size (mm),  total cross sectional area (Tt.ar, mm
2
), cortical area (Ct.Ar, mm
2
) and cortical area 
fraction (%) were measured or calculated [30, 31].  
Cytokine measurements 
The concentrations (pg/mL) of cytokines were measured in serum in duplicates using a commercial 
kit: Mouse ProInflammatory 7-Plex Ultra-Sensitive Kit (Meso scale Discovery: Rockville). The 
measurements were performed at Center of Inflammation and Metabolism, Copenhagen University 
Hospital, Rigshospitalet in accordance with manufacturer’s instructions. The coefficient of variation 
was at low, medium and high concentrations) IL1b: 8.4%; 1.8% and 3.2% (highest at lowest 
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concentration), IL-12: 8.1%; 2.3% and  4.4% , IFN-y: 7.3%; 1.0% and 2.9%, IL-6: 2.8%; 6.8% and 
4.0%; KC/GRO: 7.8%; 5.7% and 2.8%; IL-10: 4.3%; 1.1% and 5.8% and TNFα: 9.0%; 3.4% and 
2.6%  
The lower limits of detection (LLOD) were: IL1b: 0.75 pg/mL; IL-12: 35 pg/mL ; IFN-y: 0.38 
pg/mL; IL-6: 4.5 pg/mL ; KC/GRO: 3.3 pg/mL;  IL-10: 11 pg/mL and TNFα: 0.85 pg/mL 
Markers of Bone Turnover 
In order to investigate the effect of generalized inflammation and P2X7 receptor expression on bone 
turnover, serum markers of bone formation (total pro-collagen type 1 N-terminal propeptide (P1NP) 
and (C-terminal telopeptide of type 1 collagen (CTX-1)) were measured. P1NP was measured in 
serum samples in duplicate using the Rat/mouse P1NP assay from IDS (Immunodiagnostic systems 
PLC, Boldon, OK) following the protocol supplied. P1NP: precision: intra assay: 5-7.4 %. Inter-
assay: 9.2-8 %. CTX-1was measured in serum samples in duplicate using the RATlaps EIA assay 
from IDS (Immunodiagnostic systems PLC) using the suppliers instructions. Intra-assay variation: 
CV was 9.2-5.8%, Inter-assay variation: CV: 14.8-10.7 %. 
 
Statistics:  
SPSS software version 19 was used. Standard parametric tests, T-test, ANCOVA and ANOVA 
were used as appropriate. On data unlikely to be normally distributed or with a lower sample size 
non parametric Mann-Whitney tests were used. Differences were considered statistically significant 
when p < 0.05. Simple descriptives were presented as means ± standard deviation (SD) or standard 
error of the mean (SEM).  
 
Results 
The study included in total 146 mice (Figure 1).   
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At baseline, the bodyweight differed slightly between WT animals and KO mice, (28.3 ± 1.77 g vs. 
31.1 ± 2.4 g, p<0.002).  We observed no significant difference between WT vehicle animals 
compared to WT IMO mice and KO vehicle animals compared to KO IMO animals. Furthermore, 
we observed no significant change in body weight during the 10 and 20 days of the experiment; and 
no difference between the vehicle and IMO groups in both WT and KO animals.  
The spleen weight was 86.4 ± 13.2 mg in the WT animals compared to 104.3 ± 27 mg in the KO 
animals at baseline. The spleen weight increased significantly in the WT IMO mice to 131 ± 59 mg; 
p<0.005) at day 10 and to 130.8 ± 44.4; p<0.001 at day 20, whereas we observed no significant 
change in spleen weight in the WT vehicle, KO vehicle and KO IMO mice at 10 and 20 days. 
 
Bone mineral density (BMD)  
BMD at the femur and spine decreased significantly from baseline to day 20 in the WT IMO mice 
(p<0.01) (Table 1). After correction for the lower weight of the WT mice compared to KO mice the 
reduction was still significant (p=0.032). In the WT vehicle, KO vehicle and KO IMO no 
significant BMD changes were found from baseline to day 20 (Table 1). 
 
Bone strength 
In table 2 the data on bone strength measurements are presented. The data showed increased mid-
shaft max strength in WT vehicle (p=0.028) and also a non-significant trend towards higher mid-
shaft strength of the KO vehicle group at 20 days. In contrast no increase was observed in WT IMO 
(Table 2). 
 
Bone microarchitecture 
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The Micro-CT data of trabecular bone showed that bone volume fraction (BV/TV) after 20 days 
was significantly decreased in the WT IMO group (28.1%, p=0.001). The trabecular space was 
significantly higher (28.0%, p<0.001) and the trabecular number lower (13.1%, p=0.017). In 
contrast, the WT vehicle and KO vehicle BV/TV, trabecular space and trabecular number did not 
change at 20 days. The KO IMO did as well not change in BV/TV, but trabecular number 
significantly decreased (8.0 %, p=0.019) and trabecular space increased at 20 days (8.7%, p=0.041) 
to a less extend compared to WT IMO (Table 3A). Representative changes are also shown in figure 
2. 
The Micro-CT data of cortical bone showed no significant changes in cortical bone area after 20 
days in the WT IMO group, whereas the total bone area increased significantly in WT vehicle in 
KO IMO group after 20 days (5.2% and 8.8%, respectively). The mean 2d cortical bone area 
fraction was also lower in the 20 days WT IMO group compared to baseline (p=0.005), (Table 3B). 
Cytokine measurements 
Serum samples were available in sufficient amount enabling cytokine measurements from 117 of 
the 146 animals. However, 40 samples were lost due to technical error leaving only between 7-15 
samples in each group. A substantial part of the cytokine measurements were below Lower limit of 
detection or below curve fit. On IL-1β, TNF-α and IL-12 measurements data were generally lower 
than the measurements limits (data not shown), e.g. only 11 of the IL-12 measurements were not 
lower than the limit of detection (LLOD) or below curve fit (being lower than the lowest 
measurement for the standard curve and therefore measurements cannot be estimated.). 
In WT vehicle none of the measured cytokines changes significantly after 10 or 20 days compared 
to WT baseline. In KO vehicle only IL-10 was significantly increased at 20 days compared to KO 
baseline. In WT IMO - IL-10 was significantly higher at 20 days and IL-6 was significantly higher 
at 10 days compared to baseline. In KO IMO - IL-6 was significantly higher at 10 and 20 days 
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(Table 4A) compared to baseline. Comparing WT and KO in their corresponding groups, IMO 10 
days, IMO 20 days, vehicle 10 days and vehicle 20 days: IL 10 was lower at baseline; at 10 days 
vehicle both Cxcl1 and IL-10 was different; at 10 days IMO IL-10 was different; at 20 days no 
differences were found between the cytokines comparing WT and KO in both IMO and vehicle 
(Table 4A). In the WT Comparing IMO and vehicle at 10 and 20 days only 20 days IL-10 was 
significantly higher in IMO WT (p=0.006). 
Bone turnover markers 
In the WT vehicle CTX-I was significantly higher at 20 days and P1NP was significantly lower at 
10 and 20 days (p<0.001) compared to baseline. No differences were found in the WT IMO 
comparing 10 and 20 days to baseline. In KO vehicle P1NP was significantly lower at 10 days 
compared to baseline and in the KO IMO CTX-I was significantly lower at 20 days compared to 
baseline. Comparing WT and KO in their corresponding groups found both CTX-I and P1NP 
significant lower at baseline. At 20 days vehicle CTX-I were significant lower and P1NP higher in 
the KO compared to the WT. At 20 days IMO the CTX-I and P1NP was lower than in the KO. In 
the 10 day groups only P1NP were different in the WT vehicle group comparing to 10 days KO 
vehicle (Table 4B). Comparing between IMO and vehicle P1NP was significantly lower in WT 
IMO at 20 days (P=0.002). P1NP was lower in 10 days KO vehicle compared to IMO (p=0.04) but 
was borderline higher at 20 days (p=0.05). No differences were found comparing CTX-I vehicle 
and IMO groups in WT or KO. 
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Discussion 
The P2X7 receptor is a key factor in inflammatory responses and as the receptor is also important in 
the regulation of bone formation and resorption, we hypothesized that the receptor plays an 
important role in the inflammatory bone loss. Our results showed that the P2X7 receptor might play 
a significant role in the bone loss associated with the chronic inflammation in a mouse model of 
generalized inflammation. The bone loss seen in WT IMO animals was completely abolished in 
P2X7 KO animals; this was true for both BMD and for the trabecular microarchitectural 
parameters. This implies that the role of the receptor is different in bone that is not exposed to 
chronic inflammation and bone in inflammatory diseases. In previous studies on P2X7 receptor 
effects in bone, P2X7 KOs have decreased bone mass compared to WT – in our study there is a 
bone-protective effect of not expressing the P2X7 receptor. The explanation for this might be the 
role of the P2X7 receptor in the inflammatory response where P2X7 receptor activation has been 
shown to up-regulate expression of and activate the NALP3 inflammasome. Moreover, P2X7 KO 
mice have reduced cytokine release and attenuated inflammatory response compared to WT animals 
[5]. The cytokines TNFα, IL-1, IL-6 and IL-17 are known major triggers of osteoclasts and IL-12, 
IL-18, IL-33 and IFN are strong suppressors of osteoclast differentiation and inhibit bone loss [32]. 
In contrast, regulation of “normal” bone metabolism happens in an environment without low grade 
inflammation and with low levels of cytokines, and the effect of the P2X7 receptor in bone cells 
might therefore prevail compared to the effect of the receptor in the immune system. 
 
A few published studies on experimentally induced inflammation have shown to induce 
osteoporosis, though no model completely mimics autoimmune disease in humans. The IMO model 
was chosen as it gives a robust inflammatory response and as it has been shown to develop 
osteoporosis [28] . However, the exact mechanisms of the inflammatory response are relatively 
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unknown though they might involve activation of the inflammasome complex in which the P2X7 
receptor is a key factor. In our study, we found a decrease in BMD and in BV/TV in the WT IMO 
mice while the WT vehicle treated animals maintained their bone mass and structure. Also, spleen 
weights in the WT IMO animals were increased after 20 days, indicating a clear activation of the 
immune system. These findings are in line with previous findings from studies using this model and 
document the reproducibility of this model and the validity of our study. Amour et al. found that 
TALC significantly increased the NO production (2.5-fold, p < 0.005) in WT mice with IMO, but 
observed no change in iNOS KO mice. In contrast, iNOS KO mice with IMO showed less 
inhibition of bone formation than WT mice and showed no significant increase in osteoblast 
apoptosis. The authors concluded that inducible NOS-mediated osteoblast apoptosis and depressed 
bone formation might play important roles in the pathogenesis of their model [33]. 
A number of the P2X7-coupled pathways are important in both the immune response and in the 
control of bone resorption, as bone resorption is increased significantly in inflammatory-induced 
bone loss. During the inflammatory process large amounts of ATP are released; ATP is a natural 
ligand for most P2 receptors and an inflammation-induced ATP release would therefore activate a 
range of P2 receptors, including the P2X7 receptor which requires high concentrations of ATP to be 
activated. As ATP is rapidly degraded extracellularly, systemically increased levels of ATP are 
unlikely. Skeletal effects of ATP-mediated purinergic signaling through P2X7 receptors may 
therefore occur via three mechanisms. The first is the general skeletal bone loss, which might be 
induced through local activation of P2X7 receptors on immune cells inducing IL-1β and TNF-
α production, processing and release to the circulation where it induces a generalized increase in 
bone resorption through activation of osteoclasts in all parts of the skeleton. Secondly, ATP release 
as part of the inflammatory process could activate bone cells locally as the immune system and 
bone are in close contact both in the bone marrow and in affected joints. Here, activation of P2X7 
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receptors in bone cells could activate osteoclasts both through a direct activation of osteoclast 
precursors to form mature multinucleated bone-resorbing osteoclasts and through an indirect 
activation via stimulation of osteoblastic P2X7 receptors and upregulation of RANKL on 
osteoblasts, thereby inducing osteoclast formation and activity. Finally, due to reduced mobility of 
patients due to their primary inflammatory diseases, a reduced activation of P2X7 receptors in 
osteoblasts, usually mediating mechanotransduction and anabolic effects, results in reduced bone 
formation, which further aggravates the effects of the disease on the skeleton. 
The question then arises whether altered P2X7 receptor function in humans affect the risk of 
inflammatory-induced bone loss. This has been has been addressed in a recent study by Portales-
Cervantes [34],  where the authors examined the association between polymorphisms in the P2X7 
receptor and the risk of rheumatoid arthritis or systemic lupus erythematosus. Even though they 
were not able to demonstrate differences in the distribution of genotypes between patients and 
healthy controls, they found affected receptor function and cytokine production in cells from both 
rheumatoid arthritis patients and systemic lupus erythematosus patients, suggesting a possible 
involvement of the receptor in the pathogenesis in autoinflammatory diseases [34]. However, the 
study did not address the role of the receptor in the inflammatory bone loss, neither did it include a 
full genotyping for all known functional P2X7 receptor polymorphisms. Based on our in vivo 
findings, loss-of-function polymorphisms might be expected to protect against autoimmune diseases 
and the associated bone loss. This is in contrast to what has been shown in normal, healthy subjects, 
where we have demonstrated that loss-of-function of the receptor is associated with increased bone 
loss and increased fracture risk in humans while gain-of-function polymorphisms in the receptor 
were associated with increased bone mass and reduced fracture risk [35-37]. However, no studies 
have so far examined the association between chronic inflammatory diseases and the risk or severity 
of bone loss in humans and such studies are highly warranted.  
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We believe that our study provides evidence for the effects of the P2X7 receptor in inflammatory 
bone loss, as the findings are consistent over a range of evaluation methods. Both BMD, bone 
microstructure, and bone strength all points to the same conclusion.  
Furthermore, the cytokine data on IL 6 support that inflammation is induced in the model used. 
Thus, the suppressed bone loss in KO mouse demonstrates that the P2X7 receptor is responsible for 
inflammatory-mediated bone loss in this model. However, our study has also some limitations, 
especially that the data on serum bone markers in total are inconclusive and thus does not support 
neither increased nor suppressed bone loss. Our data on IL-1b and bone turnover markers were 
expected to support the observations on BMD, bone microstructure, bone strength and IL-6. 
However, measuring cytokines are well known for their low half-life, and changes in cytokine 
levels are expected throughout the experiment. Our results showed IL-1b below the level of 
detection in all situations which might be a  limitation of our study. We are  limited by the low 
blood volume in mice, and cardiac puncture was therefore chosen to maximize the available serum. 
Cardiac puncture is however difficult. It is likely that stress and tissue damage has some impact 
depending on the duration and skill of our technique in cardiac puncture. Cardiac puncture as well 
as hypnorm dormicum injection could also affect especially cytokine.  
In conclusion, our study is the first to demonstrate the effects of the P2X7 receptor on bone in 
chronic inflammation. We found that ablation of the P2X7 receptor KO in a mouse model of IMO 
protected against inflammatory bone loss and maintained bone strength in the animals. The 
potential implications for patients with inflammatory diseases are evident. However, studies in 
humans are needed to further clarify the association between P2X7 receptor function and 
autoimmune bone loss. 
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Figure 1. 
Flow diagram and group design of 146 mice included in the study 
Figure 2. 
Representative 3D bone architecture WT and KO mice at baseline, vehicle 20 days and IMO 20 
days. 
Table 1. 
Bone mineral density measured by DXA in WT and KO mice at baseline, vehicle and IMO at 10 
and 20 days. Statistical comparison was made between baseline and day 10 as well as baseline and 
371 day 20. * p<0.001. 
Table 2. 
Biomechanical bone strength measurements in WT and KO mice at baseline, vehicle and IMO at 10 
and 20 days. 
Table 3. 
Comparison of 3-D microarchitectural parameters of trabecular bone (A) and comparison of 3-D 
microarchitectural parameters and cross-sectional areas of cortical bone (B) WT and KO mice at 
baseline, vehicle and IMO at 20 days. 
Table 4. 
Table A: Cytokine measurements, * p<0.05, compared to baseline. # p<0.05 comparing between 
KO/WT in corresponding groups. £ p<0.05 comparing IMO and vehicle in corresponding groups, 
WT or KO. 3 measurements or lower resulted in data coded as missing, -. LLOD denotes Lower 
limit of detection at 50% or more.  
Table B: Bone turnover markers, *p<0.05, 10 and 20 days vs. baseline. # p<0.05 comparing 
between KO/WT in corresponding groups. £ p<0.05 comparing between IMO and vehicle in 
corresponding groups KO or WT. 
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Table 1: Bone Mineral Density 
BMD g/cm
2
  Baseline 
Mean (SD) 
10 days 
Mean (SD) 
20 days 
Mean (SD) 
WT Vehicle Total 0.0515 
(0.0018) 
0.0519 
(0.0019) 
0.0534 
(0.0015) 
Femur 0.0736  
(0.0047) 
0.0739 
(0.0040) 
0.0739 
(0.0035) 
Spine 0.0488 
(0.0034) 
0.0532 
(0.003) 
0.0508 
(0.0025) 
WT IMO Total 0.0515 
(0.0018) 
0.0579 
(0.0035) 
0.0545 
(0.0044) 
Femur 0.0736  
(0.0047) 
0.0726 
(0.0049) 
0.0695* 
(0.0050) 
Spine 0,0488 
(0.0034) 
0.0490 
(0.0037) 
0.0460* 
(0.0057) 
KO Vehicle Total 0.0521 
(0.0020) 
0.0531 
(0.0017) 
0.0539 
(0.0016) 
Femur 0,0707 
(0.0052) 
0.0733 
(0.0039) 
0.0747 
(0.0033) 
Spine 0.0520 
(0.0041) 
0.0516 
(0.0037) 
0.0513 
(0.0034) 
KO IMO Total 0.0521 
(0.0020) 
0.0560 
(0.0027) 
0.0530 
(0.0023) 
Femur 0.0707 
(0.0052) 
0.0739 
(0.0040) 
0.732 
(0.0030) 
Spine 0.0520 
(0.0041) 
0.0539 
(0.0014) 
0.0520 
(0.0043) 
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Table 2: Biomechanical bone strength 
 Max bone 
strength (MPa) 
Baseline 
Mean (SD) 
20 days 
Mean (SD) 
P-value 
WT Vehicle Midt-shaft 19.1 (2.0) 20.9 (2.0) 0.028 
Femoral neck 17.5 (2.7) 17.1 (1.3) ns 
WT IMO Midt-shaft 19.1 (2.0) 19.0 (2.4) ns 
Femoral neck 17.5 (2.7) 16.3 (2.4) ns 
KO Vehicle Midt-shaft 19.1 (2.6) 19.8 (1.3) ns 
Femoral neck 16.4 (2.7) 17.3 (2.7) ns 
KO IMO Midt-shaft 19.1 (2.6) 20.0 (1.5) ns 
Femoral neck 16.4 (2.7) 18.5 (2.2) ns 
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Table 3A. Comparison of 3-D microarchitectural parameters of trabecular bone in 4 groups  
 
 3-D Microarchitecture Baseline  
Mean (SD) 
20 days 
Mean (SD) 
P-Value 
WT 
Vehicle 
BV/TV (%)   23.5 (4.0) 23.4 (3.2) ns 
Tb.N (per mm) 4.64 (0.59) 4.60 (0.54) ns 
Tb.Th (mm) 0.06 (0.01) 0.070 (0.01) 0.052 
Tb.Sp (mm) 0.19 (0.06) 0.21 (0.03) ns 
Conn.D (mm
-3
) 158.4 (23.1) 139.5 (25.4) 0.06 
SMI (-) 1.57 (0.31) 1.48 (0.26) ns 
WT IMO BV/TV (%)   23.5 (4.0) 16.9 (5.1) 0.001 
Tb.N (per mm) 4.64 (0.59) 4.03 (0.59) 0.017 
Tb.Th (mm) 0.06 (0.01) 0.061 (0.01) ns 
Tb.Sp (mm) 0.19 (0.03) 0.25(0.04) <0.001 
Conn.D (mm
-3
) 158.4 (23.1) 106.7 (31.3) <0.001 
SMI (-) 1.57 (0.31) 1.87 (0.39) 0.042 
KO 
Vehicle 
BV/TV (%) 23.3 (4.0) 23.2 (3.4) ns 
Tb.N (per mm) 5.28 (0.33) 4.99 (0.49) ns 
Tb.Th (mm) 0.06 (0.004) 0.06 (0.005) ns 
Tb.Sp (mm) 0.18 (0.01)  0.18 (0.03) ns 
Conn.D (mm
-3
) 167.0 (23.9) 157.9 (26.8) ns 
SMI (-) 1.48 (0.18) 1.38 (0.33) ns 
KO IMO BV/TV (%) 23.3 (4.0) 22.4 (4.0) ns 
Tb.N (per mm) 5.28 (0.33) 4.86 (0.47) 0.019 
Tb.Th (mm) 0.06 (0.004) 0.06 (0.004) ns 
Tb.Sp (mm) 0.18 (0.01)  0.20 (0.02) 0.041 
Conn.D (mm
-3
) 167.0 (23.9) 140.5 (19.9) 0.006 
SMI (-) 1.48 (0.33) 1.38 (0.33) ns 
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Table 3B: Comparison of 3-D microarchitectural parameters and cross-sectional areas of 
cortical bone in 4 groups  
  Baseline  
Mean (SD) 
20 days  
Mean (SD) 
P-value 
WT 
Vehicle 
3-D Microarchitecture    
Porosity (%) 2.40 (0.14) 1.92 (0.09) 0.009 
Cort.Th (mm) 0.24 (0.01) 0.25 (0.00) ns 
BS/TV (mm
-1
) 3.50 (0.16) 4.31 (0.13) ns 
Pore size (mm) 0.04 (0.01) 0.04 (0.01) ns 
2-D cross-sectional area    
Tt.Ar (mm
2
) 2.28 (0.05) 2.40 (0.04) ns 
Ct.Ar (mm
2
) 1.17 (0.02) 1.24 (0.01) 0.008 
Ct.Ar/ Tt.Ar (%) 51.46 (0.7) 52.21 (1.2) ns 
WT IMO 3-D Microarchitecture   
Porosity (%) 2.40 (0.14) 2.53 (0.20) ns 
Cort.Th (mm) 0.24 (0.01) 0.21 (0.14) ns 
BS/TV (mm
-1
) 3.50 (0.16) 4.16 (0.28) ns 
Pore size (mm) 0.04 (0.01) 0.06 (0.03) ns 
2-D cross-sectional area    
Tt.Ar (mm
2
) 2.28 (0.05) 2.32 (0.07) ns 
Ct.Ar (mm
2
) 1.17 (0.02) 1.13 (0.04) ns 
Ct.Ar/ Tt.Ar (%) 51.46 (0.7) 48.45 (0.7) 0.005 
KO 
Vehicle 
3-D Microarchitecture     
Porosity (%) 2.00 (0.10) 1.93 (0.16) ns 
Cort.Th (mm) 0.23 (0.00)  0.23 (0.01) ns 
BS/TV (mm
-1
) 4.30 (0.13) 4.28 (0.10) ns 
Pore size (mm) 0.02 (0.01)  0.02 (0.01) ns 
2-D cross-sectional area    
Tt.Ar (mm
2
) 2.11 (0.06) 2.39 (0.04) 0.004 
Ct.Ar (mm
2
) 1.06 (0.03) 1.143 (0.01) 0.025 
Ct.Ar/ Tt.Ar (%) 50.47 (0.8) 47.97 (1.1) ns 
KO IMO 3-D Microarchitecture     
Porosity (%) 2.00 (0.10) 2.20 (0.15) ns 
Cort.Th (mm) 0.23 (0.00) 0.23 (0.00) ns 
BS/TV (mm
-1
) 4.30 (0.13) 4.00 (0.20) ns 
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Pore size (mm) 0.02 (0.01) 0.03 (0.01) ns 
2-D cross-sectional area    
Tt.Ar (mm
2
) 2.11 (0.06) 2.30 (0.04) 0.012 
Ct.Ar (mm
2
) 1.06 (0.03) 1.12 (0.01) ns 
Ct.Ar/ Tt.Ar (%) 50.47 (0.8) 48.97 (0.8) ns 
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Table 4A: Cytokine measurements 
 Cytokines pg/mL 
Baseline  
Mean (±SEM) 
10 days 
Mean (±SEM) 
20 days 
Mean (±SEM) 
WT vehicle Cxcl1 47.6 (4.7) 47.9 (13.6)# 46.1 (4.8) 
IFN 2.3 (0.6) 2.7 (1.1) 2.1 (0.4) 
IL10 21.0 (3.0)# 20.0 (2.3)# 18.2 (1.7)£ 
IL6 38.2 (14.1) 82.6 (31.0) 71.3 (11.2) 
WT IMO Cxcl1 47.6 (17.1) 54.3 (8.2) 54.9 (6.9) 
IFN 2.3 (0.6) 2.0 (0.5) 1.7 (0.1) 
IL10 21.0 (3.0)# 23.0 (3.5)  28.1 (2.3)£ 
IL6 38.2 (14.1) 96.5 (20.9)* 57.2 (11.6) 
KO vehicle Cxcl1 67.3 (11.2) 63.5 (6.4)# 56.9 (5.5) 
IFN 2.0 (1.0) 5.2 (1.6) - 
IL10 10.2 (1.0)# 14.0 (2.0)# 20.1 (2.6)* 
IL6 20.9 (10,2) 43.6 (15,4) 46.0 (12,5) 
KO IMO cxcl1 67.3 (11) 66.4 (13.6) - 
IFN 2.0 (1.0) - - 
IL10 10.2 (1.0)# 14.8 (4.6) - 
IL6 20.9 (10.2) 100.3 (51.4)* 90.8 (35.0)* 
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Table 4B: Bone turnover markers 
 Bone markers 
(serum) 
Baseline 
Mean (±SEM) 
10 days 
Mean (±SEM) 
20 days 
Mean (±SEM) 
WT vehicle 
CTX ng/ml 62.4 (8.1)# 50.6 (7.6) 88.5 (8.2)*/# 
P1NP pg/ml 67.1 (6.7)  53.2 (3.8)# 36.7 (2.8)*/#/£ 
WT IMO 
CTX ng/ml 62.4 (8,1)# 56.4 (7.0) 76,7 (8.1)# 
P1NP pg/ml 67.1 (6,7) 51.2 (6.3) 54.2 (3.7)#/£ 
KO vehicle 
CTX ng/ml 29.4 (4.4)# 46.1 (8.3) 19.4 (2.2)# 
P1NP pg/ml 49.1 (5.1)  32.7 (3.8)*/#/£ 54.9 (4.5)#/£ 
KO IMO 
CTX ng/ml 29.4 (4.4)# 59.2 (12.3) 18.1 (2.2)*/# 
P1NP pg/ml 49.1 (5.1)  42.9 (4.7)£ 40.4 (1.2)#/£ 
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Figure 2 
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Highlights 
We aimed to elucidate the role of the P2X7 receptor on bone mineral density (BMD), 
microarchitecture, and bone strength in a standardized mouse model of Inflammation-Mediated 
Osteoporosis (IMO).  
Seventy wild type (WT) mice and 76 P2X7-/- (knockout, KO) were investigated. BMD at the femur 
and spine decreased significantly from baseline to day 20 in the WT IMO mice (p<0.01). In the WT 
vehicle, KO vehicle and KO IMO, no significant BMD changes were found. 
Bone strength showed a lower mid-shaft max strength (p=0.038). Trabecular bone volume fraction 
(BV/TV) and connectivity density (CD) after 20 days were significantly decreased in the WT IMO 
group (p=0.001). In contrast, the WT vehicle and KO vehicle, BV/TV and CD did no change at 20 
days.  
The P2X7 receptor KO mice did not respond to inflammation with loss of BMD whereas the WT 
mice had a significant loss of BMD, bone strength and trabecular microarchitecture, demonstrating 
a role for the P2X7 receptor in inflammatory bone loss. 
